Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 70,686	$ 36,665
Marketable investments	47,175	90,217
Accounts receivables, net	24,190	18,715
Inventory	17,961	8,106
Prepaid expenses	7,937	11,804
Other current assets	9,008	7,482
Total current assets	176,957	172,989
Property and equipment, net	43,634	41,325
Operating lease right-of-use assets	85,261	85,173
Intangibles, net	171,440	259,705
Goodwill	80,199	79,525
Equity investments	55,605	51,271
Other assets, net	2,518	4,830
Total assets	615,614	694,818
Current liabilities:
Accounts payable	38,391	27,414
Accrued payroll and related benefits	29,197	21,503
Accrued expenses	59,764	37,975
Current portion of deferred revenue	281	1,108
Current portion of operating lease liabilities	13,373	11,539
Current portion of contingent consideration	397	397
Acquisition consideration	7,670	7,537
Current portion of debt	52,907	31,980
Total current liabilities	201,980	139,453
Long-term debt, net of discount	17,800	110,627
Deferred tax liabilities, net	1,744	2,426
Deferred revenue	117,224	118,942
Derivative liabilities		35,700
Operating lease liabilities	84,133	83,431
Contingent consideration	57,249	124,349
Other long-term liabilities	5,278	1,761
Total liabilities	485,408	616,689
Commitments and contingencies (See Note 10)
Sorrento Therapeutics, Inc. equity
Common stock, $0.0001 par value 750,000,000 shares authorized and 468,290,927 and 314,573,225 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	47	32
Additional paid-in capital	1,916,794	1,513,758
Accumulated other comprehensive income	226	1,026
Accumulated deficit	(1,735,755)	(1,386,604)
Treasury stock, 7,568,182 shares at cost at September 30, 2022, and December 31, 2021	(49,464)	(49,464)
Total Sorrento Therapeutics, Inc. stockholders’ equity	131,848	78,748
Noncontrolling interests	(1,642)	(619)
Total equity	130,206	78,129
Total liabilities and stockholders’ equity	$ 615,614	$ 694,818